Xenogeneic and allogeneic anti-MHC immune responses induced by plasmid DNA immunization

Vaccine

Volumn 17, Issue 20-21, 1999, Pages 2479-2492

  Dela Cruz, Charles S ^a   Chamberlain, John W ^a,b   MacDonald, Kelly S ^a,b   Barber, Brian H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Antibodies; DNA vaccine; MHC

Indexed keywords

DNA VACCINE; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; PLASMID DNA; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG DESIGN; FEMALE; HLA SYSTEM; IMMUNE RESPONSE; IMMUNIZATION; MACACA; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRION; VIRUS ENVELOPE;

EID: 0033522813     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00082-1     Document Type: Article

References (49)

1. Haynes B.F. HIV vaccines: where we are and where we are going. Lancet. 348:1996;933-937.
2. Sullivan N., Sun Y., Li J., Hofmann W., Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol. 69:1995;4413-4422.
3. Hoxie J.A., Fitzharris T.P., Youngbar P.R., Matthews D.M., Rackowski J.L., Radka S.F. Non-random association of cellular antigens with HTLV-III virions. Hum Immunol. 18:1987;39-52.
4. Henderson L.E., Sower R., Copeland T.D.et al. Direct identification of class II histocompatibility DR proteins in preparations of human T-cell lymphotropic virus type III. J Virol. 61:1987;629-632.
5. Arthur L.O., Bess J.W. Jr., Sowder R.C. IIet al. Cellular proteins bound to immunodeficiency viruses: Implications for pathogenesis and vaccines. Science. 258:1992;1935-1938.
6. Schols D., Pauwels R., Desmyter J., De Clercq E. Presence of class II histocompatibility DR proteins on the envelope of human immunodeficiency virus demonstrated by FACS analysis. Virology. 189:1992;374-376.
7. Bubbers J.E., Lilly F. Selective incorporation of H-2 antigenic determinants into Friend virus particles. Nature. 266:1977;458-459.
8. Azocar J., Essex M. Incorporation of HLA antigens into the envelope of RNA tumor viruses grown in human cells. Cancer Res. 39:1979;3388-3391.
9. Lee T.H., Essex M., De Noronha F., Azocar J. Neutralization of feline leukemia virus with feline antisera to leukocyte alloantigens. Cancer Res. 42:1982;3995-3999.
10. Murphey-Corb M., Martin L.N., Davison-Fairburn B.et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science. 246:1989;1293-1297.
11. Desrosiers R.C., Wyand M.S., Kodama T.et al. Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci USA. 86:1989;6353-6357.
12. Stott E.J. Anti-cell antibody in macaques. Nature. 353:1991;393.
13. Langlois A.J., Weinhold K.J., Matthews T.J., Greenberg M.L., Bolognesi D.P. Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res Hum Retroviruses. 8:1992;1641-1652.
14. Stott E.J., Chan W.L., Mills K.H.et al. Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet. 336:1990;1538-1541.
15. Chan W.L., Rodgers A., Hancock R.D.et al. Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response. J Exp Med. 176:1992;1203-1207.
16. Chan W.L., Rodgers A., Grief C.et al. Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H. AIDS. 9:1995;223-228.
17. Arthur L.O., Bess J.W. Jr., Urban R.G.et al. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol. 69:1995;3117-3124.
18. Van Gool S.W., Vandenberghe P., de Boear M., Ceuppens J.L. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Imm Reviews. 153:1996;47-83.
19. June C.H., Bluestone J.A., Nadler L.M., Thompson C.B. The B7 and CD28 receptor families. Immunol Today. 15:1994;321-331.
20. Chamberlain J.W., Nowlan J.A., Conrad P.J.et al. Tissue-specific and cell surface expression of human major histocompatibility complex class I heavy (HLA-B7) and light (beta2-microglobulin) chain genes in transgenic mice. Proc Natl Acad Sci USA. 85:1988;7690.
21. Kung S.K.P., Su R.-C., Graham J.J.K., Chamberlain J.W., Miller R.G. NK Cells from human MHC class I (HLA-B) transgenic mice do not mediate hybrid resistance killing against parental nontransgenic cells. J Immunol. 160:1998;674-680.
22. Willbanks G.A., Rootman D.S., Jay V., Wiggert B., Chamberlain J., Inman R.D. Experimental autoimmune uveitis in HLA-B27 transgenic mice. Hum Immunol. 53:1997;188-194.
23. Parham P., Brodsky F.M. Partial purification and some properties of BB7.2 - A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. Hum Immunol. 3:1981;277-299.
24. Ellis S.A., Taylor C., McMichael A. Recognition of HLA-B27 and related antigen by a monoclonal antibody. Hum Immunol. 5:1982;49-59.
25. Storkus W.J., Howell D.N., Salter R.D., Dawson J.R., Cresswell P. NK susceptibility varies inversely with target cell class I HLA antigen expression. J Immunol. 138:1987;1657-1659.
26. Matsui M., Moots R.J., McMichael A.J., Frelinger J.A. Significance of the six peptide-binding pockets of HLA-A2.1 in influenza A matrix pepetide-specific cytotoxic T-lymphocyte reactivity. Hum Immunol. 41:1994;160-166.
27. Storkus W.J., Alexander J., Payne J.A., Dawson J.R., Cresswell P. Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes. Proc Natl Acad Sci USA. 86:1989;2361-2364.
28. Dubiski S., Cinader B., Chou C.T., Charpentier L., Letarte M. Cross-reaction of a monoclonal antibody to human MHC class II molecules with rabbit B cells. Mol Immunol. 25:1988;713-718.
29. Iwasaki A., Stiernholm B.J.N., Chan A.K., Berinstein N.L., Barber B.H. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol. 158:1997;4591-4601.
30. Mellon P., Parker V., Gluzman Y., Maniatis T. Identification of DNA sequences required for transcription of the human alpha1-globin gene in a new SV40 host-vector system. Cell. 27:1981;279-288.
31. Eisenbraun M.D., Fuller D.H., Haynes J.R. Examination of parameters affecting the elicitation of humoral immune responses by particle bombardment-mediated genetic immunization. DNA Cell Biol. 12:1993;791-797.
32. Cantin R., Fortin J.-F., Lamontagne G., Tremblay M. The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. J Virology. 71:1997;1922-1930.
33. Zemmour J., Little A.-M., Schendel D.J., Parham P. The HLA-A, B 'negative' mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol. 148:1992;1941-1948.
34. Stott E.J., Schild G.C. Strategies for AIDS vaccine. J Antimicrobial Chemotherapy. 37:1996;185-198.
35. Cranage M.P., Polyanskaya N., McBride B.et al. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retroviruses. 9:1993;13-22.
36. Stott E.J., Almond N., West W., Kent K., Kranage M.P., Rud E. Girard M., Dodet B.)., Retroviruses of human A.I.D.S. and related animal diseases: Colloque des Cent Gardes (eds. 1994);219-224 Pasteur vaccins, Marnes-la-Coquette.
37. MacDonald K.S., Embree J., Njenga S.et al. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type I transmission. J Infect Dis. 177:1998;551-556.
38. Gulukota K., DeLisi C. HLA allele selection for designing peptide vaccines. Genetic Analysis: Biomolecular Engineering. 13:1996;81-86.
39. Mellors J.W., Rinaldo C.R. Jr., Gupta P., White R.M., Todd J.A., Kingsley L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 272:1996;1167-1170.
40. Polyanskaya N., Sharpe S., Cook N.et al. Anti-major histocompatiblity complex antibody responses to simian B cells do not protect macaqeus against SIVmac infection. AIDS Res Hum Retroviruses. 12:1997;923-931.
41. Luscher M.A., Dela Cruz C.S., MacDonald K.S., Barber B.H. Concerning the anti-major histocompatibility complex approach to HIV-1 vaccine design. AIDS Res Hum Retroviruses. 14:1998;541-544.
42. Kim J.J., Bagarazzi M.L., Trivedi N.et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol. 15:1997;641-646.
43. Charron D.J., Aellen-Schulz M.F., St. Geme J.R., Erlich H.A., McDevitt H.O. Biochemical characterization of an invariant polypeptide associated with Ia antigens in human and mouse. Mol Immunol. 20:1983;21-32.
44. Miller J., Germain R.N. Efficient cell surface expression of class II MHC molecules in the absence of associated invariant chain. J Exp Med. 164:1986;1478-1489.
45. Sekaly R.P., Tonnelle C., Strubin M., Mach B., O L.E. Cell surface expression of class II histocompatibility antigens occurs in the absence of the invariant chain. J Exp Med. 164:1986;1490-1504.
46. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu Rev Immunol. 15:1997;617-648.
47. Nabel G.J., Nabel E.G., Yang Z.-Y.et al. Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity and lack of toxicity in humans. Proc Natl Acad Sci USA. 90:1993;11307-11311.
48. Nabel G.J., Gordon D., Bishop D.K.et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA. 93:1996;15388-15393.
49. Stopeck A.T., Hersh E.M., Akporiaye E.T.et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncology. 15:1997;341-349.